FDA-approved1,2Evidence: Smaller human trialsInflammation and immune

Icatibant1

Also called Firazyr1,2

Key takeaway

Icatibant is a synthetic decapeptide that blocks the bradykinin B2 receptor, and the active ingredient in Firazyr.1,2 FDA approved Firazyr in 2011 to treat acute attacks of hereditary angioedema (HAE), a genetic condition that causes episodes of severe swelling, in adults.1,2 In a randomized, placebo-controlled trial, symptoms halved in a median of 2.0 hours with icatibant versus 19.8 hours with placebo, according to the label.1

Icatibant at a glance

What it isA synthetic decapeptide containing five non-standard amino acids that competitively blocks the bradykinin B2 receptor, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Firazyr with an original approval date of August 25, 2011. The cited label has no boxed warning.1,2
Human evidenceThree controlled trials in 223 adults with acute HAE attacks, including a randomized, double-blind, placebo-controlled trial in 98 adults, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is icatibant?

Icatibant is a synthetic peptide of ten amino acids, five of which are not found in natural proteins, according to the label.1

In the United States it is the active ingredient of Firazyr, from Takeda, according to Drugs@FDA.2

How does icatibant work?

The label explains that HAE is caused by missing or faulty C1-esterase inhibitor, which leads to excess bradykinin, a substance thought to cause the swelling, inflammation and pain of attacks.1

Icatibant is a selective, competitive blocker of the bradykinin B2 receptor and stops bradykinin from binding it, according to the label.1

What do human studies show?

In Trial 1, a randomized, double-blind, placebo-controlled trial, the median time to a 50% reduction in skin and abdominal symptoms was 2.0 hours with icatibant (43 patients) and 19.8 hours with placebo (45 patients), according to the label.1

In the same trial, 7% of patients on icatibant and 40% on placebo used additional rescue medication, according to the label.1

Across the three controlled trials, the median time to a 50% reduction in symptoms ranged from 2.0 to 2.3 hours, and results for throat (laryngeal) attacks were similar, according to the label.1

What the evidence base contains

  • Controlled human trial Trial 1: a randomized, double-blind, placebo-controlled trial in 98 adults with acute HAE attacks, described in the label.1
  • Controlled human trial A second placebo-controlled trial and an active-controlled trial, which with Trial 1 included 223 patients, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is icatibant FDA-approved?

Yes. Drugs@FDA lists Firazyr, application NDA 022150, with an original approval date of August 25, 2011.2

The Firazyr label cited here (DailyMed SPL version 19, published July 17, 2025) states that it is indicated for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.1

The label has no boxed warning and lists no contraindications. It warns that after treatment of a throat attack, patients should seek immediate medical attention because of the risk of airway obstruction.1

Timeline

  1. FDA approves Firazyr, according to Drugs@FDA.2
  2. DailyMed publishes the Firazyr label version cited on this page.1

What is still unknown?

Its use in children, since the approved indication in the label covers adults 18 and older.1

Whether it prevents attacks: the label covers treatment of acute attacks, not prevention.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Icatibant: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Icatibant are a bounded selection, not every registration or paper about Icatibant. For the years before Icatibant was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Icatibant as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Icatibant in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Firazyr for acute attacks of hereditary angioedema. Controlled trials described in the label, including a randomized, placebo-controlled trial of 98 adults, found faster symptom relief with icatibant.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Icatibant?

FDA-approved as Firazyr for acute attacks of hereditary angioedema. Controlled trials described in the label, including a randomized, placebo-controlled trial of 98 adults, found faster symptom relief with icatibant.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
15
Drugs@FDA applications
11

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.↗Source date November 8, 2026
  2. Clinical trials · added November 15, 2026

    ClinicalTrials.gov record NCT05834777↗Source date October 22, 2026
  3. Literature metadata · added November 15, 2026

    On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation.↗Source date August 28, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Icatibant?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

64Selected dated records
66Connected citations
15Populated source years2007–2026
3/4Record lanes present

Registered human studies

Trial composition

17 of 19 selected trial records include at least one phase value; 19 of 19 include a status value in the retained structured contract.

PhasesPhase 3 11Phase 2 5Phase 4 2Phase 1 1
Status at observationCompleted 17Active, not recruiting 2

A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 26Review 10Research Support, Non-U.S. Gov't 4Case Reports 3Letter 3Randomized Controlled Trial 2Research Support, N.I.H., Extramural 2Clinical Trial, Phase I 1Clinical Trial, Phase III 1Comment 1Comparative Study 1Editorial 1Multicenter Study 1Systematic Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
11
FDA Federal Register documents
4
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
64

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 64 dated records

Research hub

Explore the Icatibant evidence record

Open all 64 records →
64Dated records
3Evidence types
64Cited public sources
15Source years

Change ledger

Recently changed for Icatibant

Open all 64 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00097695

PeptideScanner retained ClinicalTrials.gov record NCT00097695 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.

PeptideScanner change date
November 15, 2026
Cited source date
June 9, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00223704

PeptideScanner retained ClinicalTrials.gov record NCT00223704 at 2026-11-15T22:04:12.435Z. Its registry update date was 2013-11-25, and PeptideScanner's reviewed identity mapping was icatibant.

PeptideScanner change date
November 15, 2026
Cited source date
November 25, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00500656

PeptideScanner retained ClinicalTrials.gov record NCT00500656 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.

PeptideScanner change date
November 15, 2026
Cited source date
June 9, 2021
Evidence lane
Clinical trials

Official-source collections

Source records for Icatibant

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review.Allergy and asthma proceedings · 2026 Jul 01
  2. First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2026 05 30
  3. On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation.Genes & diseases · 2026 05 14
Explore all selected literature →
ClinicalTrials.gov19

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05834777Registry update October 22, 2026 · current at observation
  2. NCT04113109Registry update August 11, 2026 · completed at observation
  3. NCT05509569Registry update August 7, 2026 · completed at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA11

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA213773Full FDA chronology · original submission status AP 2024-06-14
  2. ANDA213521Full FDA chronology · original submission status AP 2023-08-14
  3. ANDA213222Full FDA chronology · original submission status AP 2021-05-21
  4. ANDA212081Full FDA chronology · original submission status AP 2020-12-16
  5. ANDA213054Full FDA chronology · original submission status AP 2020-10-05
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Icatibant →

Evidence types

Coverage by source year

Selected records span December 21, 2007 to November 8, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 64

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.↗

    PubMed lists PMID 24749847 in Clinical and experimental immunology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2014-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05834777↗

    PeptideScanner retained ClinicalTrials.gov record NCT05834777 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was icatibant.↗

  3. Literature metadata

    On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation.↗

    PubMed lists PMID 42656409 in Genes & diseases as Editorial, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04113109↗

    PeptideScanner retained ClinicalTrials.gov record NCT04113109 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was icatibant.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT05509569↗

    PeptideScanner retained ClinicalTrials.gov record NCT05509569 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was icatibant.↗

  6. Literature metadata

    First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib.↗

    PubMed lists PMID 42219034 in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases as Journal Article, Case Reports, with publication-date metadata of 2026-05-30 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review.↗

    PubMed lists PMID 42343494 in Allergy and asthma proceedings as Journal Article, Systematic Review, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells.↗

    PubMed lists PMID 41008531 in Biomolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-25 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT04488081↗

    PeptideScanner retained ClinicalTrials.gov record NCT04488081 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-03-16, and PeptideScanner's reviewed identity mapping was icatibant.↗

  10. Literature metadata

    In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant.↗

    PubMed lists PMID 36641883 in Journal of photochemistry and photobiology. B, Biology as Journal Article, with publication-date metadata of 2023-01-10 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Icatibant in viral infections.↗

    PubMed lists PMID 37067851 in Infectious diseases (London, England) as Letter, Comment, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Assessing the performance of new chromatographic technologies for the separation of peptide epimeric impurities: the case of Icatibant.↗

    PubMed lists PMID 38142950 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2023-12-22 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FIRAZYR (icatibant acetate) injection, solution · SPL version 19 · published 2025-07-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: FIRAZYR (icatibant acetate), NDA 022150 · original approval August 25, 2011 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026